3D render of exosomes being released from a cell
FOUNDATIONAL

Exosomes: The Cell-Free Revolution in Regenerative Medicine

Explore the cell-free revolution in regenerative medicine. Learn how MSC-derived exosomes deliver therapeutic benefits, reduce inflammation, and prepare your body for optimal stem cell response.

Medical Content Team Content Team
February 10, 2026 · 22 min read

Key Takeaways

  • Exosomes are nano-sized messengers: tiny vesicles (30-150 nm) secreted by cells that carry regenerative signals throughout the body
  • They deliver the therapeutic payload of stem cells without the cells themselves: a paradigm shift in regenerative medicine
  • MSC-derived exosomes contain powerful cargo: microRNAs, proteins, lipids, and growth factors that modulate inflammation, promote healing, and carry anti-aging signals
  • Umbilical cord MSC exosomes are particularly potent: research shows they can rejuvenate aged cells and even increase telomere length
  • Exosomes work synergistically with MSC therapy: used as Day 1 preparation, they reduce inflammation and prime tissues for optimal stem cell response
  • Cell-free therapy offers practical advantages: easier standardization, no cell viability concerns, potentially longer shelf life, and simplified regulatory pathway
  • Clinical applications are expanding rapidly: orthopedics, wound healing, neurological conditions, cardiac repair, and anti-aging
  • This represents the future of regenerative medicine: harnessing cellular communication without cellular complexity

The Problem: Why Cells Aren't Always the Answer

If you're researching stem cell therapy, you've likely focused on the cells themselves. That's natural—they're called "stem cells" after all.

But here's what cutting-edge research reveals: Much of what makes stem cell therapy work isn't the cells—it's what the cells release.

This realization has sparked a revolution in regenerative medicine. What if we could capture the therapeutic benefits of stem cells in a simpler, more standardized form? What if we could prepare your body to respond optimally before stem cells are even administered?

Enter exosomes—the cell-free frontier of regenerative therapy.

What Are Exosomes?

The Basic Concept

Exosomes are extracellular vesicles—tiny membrane-bound packages that cells release to communicate with other cells. Think of them as biological "care packages" that deliver instructions and supplies from one cell to another.

Key characteristics:

To put the size in perspective: if a human cell were the size of a basketball, an exosome would be the size of a small marble.

How Exosomes Are Made

Exosomes form through a fascinating cellular process: [2]

  1. Endosome formation: The cell membrane folds inward, creating an internal compartment
  2. Cargo loading: The cell packages specific molecules (proteins, RNAs) into small vesicles within the endosome
  3. Multivesicular body: These internal vesicles accumulate, creating a "multivesicular body" (MVB)
  4. Release: The MVB fuses with the cell membrane, releasing the internal vesicles as exosomes
  5. Travel and uptake: Exosomes travel through body fluids and are taken up by recipient cells

This isn't random—cells selectively package specific cargo based on their state and the signals they're responding to. MSCs responding to inflammation, for example, package anti-inflammatory cargo.

The Exosome Communication Network

Every cell in your body releases exosomes. This creates a vast communication network:

  • Immune cells release exosomes to coordinate immune responses
  • Cancer cells release exosomes that can promote tumor spread (a target for cancer research)
  • Stem cells release exosomes carrying regenerative signals
  • Neurons release exosomes for brain cell communication

The therapeutic insight: If we harvest exosomes from the right source (MSCs), we can deliver concentrated regenerative signals to the body.

MSC-Derived Exosomes: The Therapeutic Payload

Why MSC Exosomes Are Special

Not all exosomes are created equal. MSC-derived exosomes carry a unique therapeutic cargo that reflects the regenerative properties of their parent cells. [3]

What makes them therapeutic:

  • They inherit the immunomodulatory properties of MSCs
  • They carry growth factors that promote tissue repair
  • They contain microRNAs that regulate gene expression in recipient cells
  • They can cross biological barriers (including the blood-brain barrier) that cells cannot easily penetrate
  • They're well-tolerated with minimal immune reaction

The MSC Exosome Cargo

MSC exosomes contain a sophisticated array of bioactive molecules: [4]

Proteins and Growth Factors

MicroRNAs (miRNAs)

MicroRNAs are small RNA molecules that regulate gene expression. MSC exosomes are particularly rich in therapeutic miRNAs: [5]

The miRNA advantage: Unlike proteins that act on cell surfaces, miRNAs enter cells and directly influence gene expression—a more fundamental level of regulation.

Lipids and Other Molecules

MSC exosomes also carry:

  • Phospholipids with signaling functions
  • Cholesterol for membrane stability
  • Sphingomyelin involved in cell signaling
  • Ceramides that regulate cell fate

Source Matters: Umbilical Cord MSC Exosomes

Just as UC-MSCs have advantages over adult-derived MSCs, UC-MSC exosomes carry superior regenerative cargo.

The Anti-Aging Exosome Discovery

A landmark 2021 study in Science Translational Medicine made a remarkable discovery about UC-derived extracellular vesicles: [1]

Key findings:

  • UC-MSC exosomes contain "abundant anti-aging signals"
  • They can rejuvenate aged bone marrow MSCs
  • They increase telomere length in aged cells
  • They reduce age-related organ degeneration
  • They transfer PCNA (proliferating cell nuclear antigen), a key factor in cell replication

The implication: Exosomes from young umbilical cord cells can transfer "youth signals" to aged tissues—a profound finding for anti-aging medicine.

Why UC-MSC Exosomes Lead

The Paracrine Revolution: How We Got Here

The Original Assumption

Early stem cell research assumed therapeutic effects came from engraftment and differentiation—stem cells would travel to damaged tissue, integrate, and become new cells.

The problem: Studies consistently showed:

  • Most injected MSCs die or are cleared within days [6]
  • Very few MSCs actually differentiate into tissue-specific cells
  • Yet therapeutic benefits persisted

The question: If the cells don't stay, why do patients improve?

The Paradigm Shift

Researchers discovered that MSCs work primarily through paracrine signaling—releasing factors that influence surrounding cells. [7]

Key evidence:

  1. Conditioned medium studies: Culture medium from MSCs (without cells) could reproduce many therapeutic effects
  2. Timing studies: Benefits appeared before engraftment could occur
  3. Tracking studies: Labeled MSCs disappeared while therapeutic effects persisted

Exosomes as the Primary Mediator

Further research identified exosomes as a key component of the MSC secretome: [8]

  • MSC exosomes could reproduce MSC effects in multiple disease models
  • Blocking exosome release reduced MSC therapeutic efficacy
  • Purified exosomes matched or exceeded MSC effects in some studies

This led to a revolutionary proposition: Perhaps we don't need cells at all—just their exosomes.

Exosomes vs. Whole Cell Therapy: Understanding the Differences

Comparative Analysis

When Exosomes May Excel

Advantages of exosome therapy:

  1. No cell viability concerns: Cells must be alive; exosomes are stable
  2. Potentially longer shelf life: Less fragile than living cells
  3. Easier standardization: Can be characterized and quantified
  4. Lower immunogenicity: Even less immune reaction than MSCs
  5. Nano-size access: Can reach areas cells cannot (brain, dense tissues)
  6. No tumor risk: Without cells, no possibility of cell-based tumors
  7. Simpler logistics: No cryopreservation chain required

When Cells May Be Preferable

Advantages of whole cell therapy:

  1. Responsive secretion: Cells adapt their secretome to the local environment
  2. Prolonged release: Cells continue producing factors over time
  3. Feedback loops: Cells respond to signals from recipient tissues
  4. Established evidence: More clinical trial data available
  5. Multiple mechanisms: Cells may have effects beyond secretion

The Synergistic Approach

Rather than viewing this as either/or, leading protocols combine exosomes and cells:

Day 1: Exosome Preparation

  • Reduce systemic inflammation
  • Prime tissues for regeneration
  • Deliver immediate anti-aging signals
  • Prepare the microenvironment

Day 2+: MSC Therapy

  • Deliver living cells to optimally prepared tissue
  • Cells encounter reduced inflammation
  • Enhanced engraftment potential
  • Continued paracrine effects

This combination may be more effective than either alone—the exosomes create optimal conditions for the cells to work.

The Science of Preparation: Why Day 1 Matters

The Inflammatory Challenge

When tissue is damaged or inflamed, it creates a hostile environment for regeneration:

  • Pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) dominate
  • Oxidative stress damages cells
  • Fibrotic signals promote scarring over healing
  • Immune cells are in attack mode

MSCs injected into this environment face challenges:

  • Reduced survival
  • Impaired function
  • Suboptimal engraftment

Exosomes as Environmental Modulators

Exosomes administered before MSCs can shift the inflammatory balance: [9]

Anti-inflammatory effects:

  • Reduce TNF-α production
  • Decrease IL-1β levels
  • Increase anti-inflammatory IL-10
  • Polarize macrophages toward healing (M2) phenotype

Tissue preparation effects:

  • Reduce oxidative stress
  • Inhibit fibrosis pathways
  • Promote angiogenesis (blood vessel formation)
  • Signal resident cells to prepare for regeneration

The "Prepared Garden" Analogy

Think of your body's tissues like a garden:

Without preparation (MSCs into inflamed tissue):

  • Planting seeds in hard, rocky soil
  • Harsh conditions reduce germination
  • Limited growth potential

With exosome preparation:

  • Tilling the soil, removing rocks
  • Adding nutrients, adjusting pH
  • Creating optimal conditions for growth
  • Seeds (MSCs) can thrive

This is why Day 1 preparation with exosomes may significantly enhance Day 2+ MSC therapy outcomes.

Clinical Applications: Where Exosome Research Stands

Orthopedic and Musculoskeletal

Osteoarthritis:

Preclinical studies show MSC exosomes can: [10]

  • Reduce cartilage degradation
  • Decrease inflammatory markers
  • Promote chondrocyte proliferation
  • Inhibit synovitis (joint lining inflammation)

Bone repair:

Exosomes promote osteogenesis through: [11]

  • BMP-2 pathway activation
  • miRNA-mediated osteogenic signaling
  • Enhanced bone mineral deposition

Tendon and ligament:

Studies demonstrate: [12]

  • Enhanced tenocyte proliferation
  • Improved collagen organization
  • Reduced inflammation at injury sites

Wound Healing and Dermatology

MSC exosomes show remarkable wound healing properties: [13]

  • Accelerated closure: Faster epithelialization
  • Reduced scarring: Anti-fibrotic effects
  • Enhanced angiogenesis: Better blood supply to healing tissue
  • Skin rejuvenation: Potential cosmetic applications

Neurological Applications

The nano-size of exosomes allows them to cross the blood-brain barrier: [14]

Stroke:

  • Reduced infarct size in animal models
  • Enhanced neurological recovery
  • Promoted neurogenesis and angiogenesis

Neurodegenerative diseases:

  • Alzheimer's: Reduced amyloid burden, improved cognition in models
  • Parkinson's: Protected dopaminergic neurons
  • Active research area with promising preclinical data

Cardiac Applications

MSC exosomes show cardioprotective effects: [15]

  • Reduced infarct size after heart attack
  • Improved cardiac function
  • Enhanced angiogenesis in ischemic tissue
  • Anti-fibrotic effects reducing scar formation

Anti-Aging and Longevity

Perhaps the most exciting frontier—exosomes as anti-aging therapy:

The evidence:

  1. Telomere extension: UC-MSC exosomes can increase telomere length [1]
  2. Cellular rejuvenation: Aged MSCs showed restored proliferative capacity
  3. Organ protection: Reduced age-related degeneration in animal models
  4. Senescence reversal: Decreased senescence markers in aged cells
  5. Frailty reduction: A Phase II RCT demonstrated that allogeneic MSCs improved physical performance and reduced inflammatory markers in elderly patients with frailty. [16]This was powerfully reinforced by a 2024 Phase I/II randomized, double-blind, placebo-controlled trial using UC-MSCs specifically—the same cell type whose exosomes carry the anti-aging cargo described above. Over 6 months, UC-MSC recipients showed significant improvements in quality of life (SF-36 physical component, p=0.042), grip strength (p=0.002), and physical performance (Timed Up and Go test, p<0.05), alongside reductions in the pro-inflammatory cytokines TNF-α and IL-17 (p=0.034 and p=0.033, respectively) with no difference in adverse events versus placebo. [20]

The clinical significance: These two trials—spanning 2017 to 2024—demonstrate a consistent pattern: UC-MSCs combat frailty through the very mechanisms exosome research predicts. The inflammation reduction (TNF-α, IL-17) and functional improvements align precisely with the anti-aging cargo (miR-let7, PCNA, telomerase factors) documented in UC-MSC exosomes. The cells work, in large part, because their exosomes work.

The mechanism: Young exosomes transfer "youth signals" (specific miRNAs, proteins, telomerase-associated factors) to aged cells, essentially reprogramming them toward a younger phenotype.

Manufacturing and Quality Considerations

Production Methods

MSC exosomes are produced through a multi-step process: [17]

  1. MSC culture: Expand MSCs under controlled conditions
  2. Conditioning: Culture MSCs in serum-free or exosome-depleted medium
  3. Collection: Harvest conditioned medium containing exosomes
  4. Isolation: Separate exosomes from other components
  5. Characterization: Verify identity and quality
  6. Formulation: Prepare for clinical use
  7. Storage: Typically -80°C or lyophilized
    • Ultracentrifugation
    • Size exclusion chromatography
    • Immunoaffinity capture
    • Tangential flow filtration

Quality Attributes

The International Society for Extracellular Vesicles (ISEV) has established guidelines: [18]

Identity markers:

  • Tetraspanins (CD9, CD63, CD81)
  • TSG101, Alix (biogenesis markers)
  • MSC markers on surface

Purity measures:

  • Absence of cellular contaminants
  • Protein-to-particle ratio
  • Absence of aggregates

Potency assays (developing field):

  • Functional assays (immunosuppression, wound healing)
  • miRNA profiling
  • Protein cargo analysis

Standardization Challenges

Despite advantages, exosome standardization faces hurdles:

  • No universal potency assay: How do we measure "dose"?
  • Isolation method effects: Different methods yield different products
  • Batch variability: Even from same MSC source
  • Quantification: Particle counting vs. protein content vs. specific markers

The field is rapidly advancing, with consensus guidelines emerging.

Safety Profile

Theoretical Advantages

Exosomes have inherent safety advantages over cells:

  • No replication: Cannot multiply uncontrollably
  • No differentiation: Cannot form unwanted tissues
  • Minimal immunogenicity: Low surface MHC expression
  • No long-term persistence: Cleared relatively quickly

Preclinical Evidence

Animal studies consistently show excellent safety: [19]

  • No tumor formation
  • No significant immune reactions
  • No organ toxicity at therapeutic doses
  • No adverse effects on hematology or chemistry

Clinical Experience

Human studies, while still limited, report favorable safety:

Published trials and case series show:

  • No serious adverse events attributed to exosomes
  • Mild injection site reactions (rare)
  • No immunological complications
  • No delayed adverse effects in follow-up

Considerations

Areas requiring continued investigation:

  • Long-term effects of repeated dosing
  • Effects in immunocompromised patients
  • Optimal dosing parameters
  • Potential interactions with other therapies

Exosomes in the Treatment Protocol

The Integrated Approach

Understanding how exosomes fit into a comprehensive regenerative protocol:

Pre-Treatment Assessment

Before any therapy:

  • Baseline inflammatory markers
  • Health optimization review
  • Contraindication screening

Day 1: Foundation Protocol

Morning:

  • Blood panel and baseline assessment
  • NAD+ infusion (cellular energy support)
  • Exosome administration

Exosome goals:

  • Begin inflammatory modulation
  • Deliver anti-aging signals
  • Prepare tissue microenvironment
  • Support cellular energy

Afternoon:

  • Rest and hydration
  • Optional supportive therapies (IV nutrients)

Day 2+: MSC Therapy

With inflammation reduced and tissues primed:

  • MSC administration (50-100M total UC-MSCs)
  • Cells encounter optimized environment
  • Enhanced therapeutic response

Follow-up

  • Repeat inflammatory markers
  • Functional assessments
  • Optional maintenance protocols

Why This Sequence Matters

The logic:

  1. Exosomes act fast: Begin modulating inflammation within hours
  2. MSCs need time: Cell effects develop over days to weeks
  3. Synergy: Prepared environment + living cells = enhanced outcomes
  4. Practical: Allows assessment between treatments

Frequently Asked Questions

What's the difference between exosomes and stem cells?

Stem cells are living cells that can self-renew and differentiate. Exosomes are tiny vesicles that cells release for communication. MSC exosomes carry many of the therapeutic signals that make MSC therapy effective, but without the cells themselves.

Think of it this way: If MSCs are factories, exosomes are the products those factories ship out. We can use the products directly without maintaining the entire factory at the treatment site.

Are exosomes FDA approved?

Currently, no exosome products have FDA approval for regenerative medicine indications. However:

  • Multiple clinical trials are underway
  • The regulatory pathway may be simpler than for cells
  • Exosomes are used clinically in other countries
  • The FDA has shown interest in this emerging field

How are exosomes administered?

Depending on the application:

  • Intravenous (IV): For systemic effects
  • Intra-articular: Direct injection into joints
  • Topical: For wound healing and skin applications
  • Intrathecal: For neurological conditions (research)

How long do exosome effects last?

This varies by application and individual. Exosomes themselves are cleared within hours to days, but the cellular changes they induce can persist:

  • Gene expression changes may last weeks to months
  • Anti-inflammatory effects can be prolonged
  • Tissue repair effects continue after exosome clearance

For optimization and anti-aging, some protocols recommend periodic treatments.

Can I get exosome therapy without stem cells?

Yes, exosome therapy can be administered as a standalone treatment. However, for comprehensive regenerative protocols, combining exosomes (Day 1 preparation) with MSC therapy (Day 2+) may provide synergistic benefits.

Are exosomes safe?

The safety profile is excellent based on available evidence:

  • No tumor risk (non-replicating)
  • Minimal immune reaction
  • No serious adverse events in clinical studies
  • Well-tolerated in human applications

Where do therapeutic exosomes come from?

The highest quality therapeutic exosomes are derived from umbilical cord MSCs:

  • Neonatal source (no aging effects)
  • Abundant anti-aging signals
  • Consistent, characterized source
  • Ethically uncontroversial

How are exosomes different from PRP?

PRP (Platelet-Rich Plasma) contains growth factors from your own blood platelets. MSC exosomes contain the regenerative cargo from stem cells, including miRNAs that regulate gene expression—a more sophisticated level of biological modulation.

How many exosomes are in a treatment?

Dosing is still being optimized, but treatments typically contain:

  • Billions of exosome particles
  • Measured by particle count (NTA analysis)
  • And/or protein content
  • From defined number of source MSCs

The Future of Exosome Therapy

Emerging Directions

Engineered exosomes:

  • Loading specific therapeutic cargo
  • Surface modifications for targeting
  • Enhanced potency through selection

Combination approaches:

  • Exosomes + small molecules
  • Exosomes + gene therapy
  • Multi-source exosome cocktails

Personalization:

  • Exosomes from specific MSC subpopulations
  • Condition-specific formulations
  • Response-guided dosing

Expanded applications:

  • Cancer (as delivery vehicles)
  • Infectious diseases
  • Metabolic conditions
  • Aging and longevity

The Convergence

We're witnessing a convergence of technologies:

  • Nanotechnology: Understanding and engineering nano-scale biology
  • Regenerative medicine: Harnessing the body's repair mechanisms
  • Anti-aging science: Targeting fundamental aging processes
  • Precision medicine: Personalized therapeutic approaches

Exosomes sit at the intersection of these fields, offering a versatile platform for next-generation therapeutics.

Take the Next Step

Exosome therapy represents the cutting edge of regenerative medicine—delivering the therapeutic essence of stem cells in an elegant, cell-free format. As Day 1 preparation for MSC therapy, exosomes help create optimal conditions for regeneration.

→ Take Our 2-Minute Health Assessment

Find out if regenerative therapy might be appropriate for you

→ Download: The Complete Guide to Regenerative Protocols

Understand how exosomes, NAD+, and MSCs work together

→ Read Next: Combination Therapies—Why Multi-Modal Approaches Work Better

Learn about the synergy of combined regenerative treatments

→ Schedule a Discovery Call

Speak with a specialist about your specific situation

This content is for educational purposes only and does not constitute medical advice. Exosome therapies vary in regulatory status by country and are considered investigational in many jurisdictions. Individual results vary significantly. Always consult with a qualified healthcare provider before making treatment decisions.

References

  1. Lei, Q., Gao, F., Liu, T., Ren, W., Chen, L., Cao, Y., Chen, W., Guo, S., Zhang, Q., Chen, W., Wang, H., Chen, Z., Li, Q., Hu, Y. and Guo, A. (2021). Extracellular vesicles deposit PCNA to rejuvenate aged bone marrow-derived mesenchymal stem cells and slow age-related degeneration. , 13 doi:10.1126/scitranslmed.aaz8697 Tier 1
  2. Théry, C., Witwer, K.W., Aikawa, E., Alcaraz, M.J., Anderson, J.D., Andriantsitohaina, R., et al. (2018). Minimal information for studies of extracellular vesicles 2018 (MISEV2018): A position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. , 7 doi:10.1080/20013078.2018.1535750 Tier 1
  3. Phinney, D.G. and Pittenger, M.F. (2017). Concise review: MSC-derived exosomes for cell-free therapy. , 35 , pp. 851–858 doi:10.1002/stem.2575 Tier 1
  4. Harrell, C.R., Jovicic, N., Djonov, V., Arsenijevic, N. and Volarevic, V. (2019). Mesenchymal stem cell-derived exosomes and other extracellular vesicles as new remedies in the therapy of inflammatory diseases. , 8 doi:10.3390/cells8121605 Tier 1
  5. Ferguson, S.W., Wang, J., Lee, C.J., Liu, M., Neelamegham, S., Canty, J.M. and Bhang, H. (2018). The microRNA regulatory landscape of MSC-derived exosomes: A systems view. , 8 doi:10.1038/s41598-018-19581-x Tier 1
  6. von Bahr, L., Batsis, I., Moll, G., Hägg, M., Szakos, A., Sundberg, B., Uzunel, M., Ringden, O. and Le Blanc, K. (2012). Analysis of tissues following mesenchymal stromal cell therapy in humans indicates limited long-term engraftment and no ectopic tissue formation. , 30 , pp. 1575–1578 doi:10.1002/stem.1118 Tier 1
  7. Caplan, A.I. (2017). Mesenchymal stem cells: Time to change the name!. , 6 , pp. 1445–1451 doi:10.1002/sctm.17-0051 Tier 1
  8. Lai, R.C., Arslan, F., Lee, M.M., Sze, N.S., Choo, A., Chen, T.S., Salto-Tellez, M., Timmers, L., Lee, C.N., El Oakley, R.M., Pasterkamp, G., de Kleijn, D.P. and Lim, S.K. (2010). Exosome secreted by MSC reduces myocardial ischemia/reperfusion injury. , 4 , pp. 214–222 doi:10.1016/j.scr.2009.12.003 Tier 1
  9. Ti, D., Hao, H., Tong, C., Liu, J., Dong, L., Zheng, J., Zhao, Y., Liu, H., Fu, X. and Han, W. (2015). LPS-preconditioned mesenchymal stromal cells modify macrophage polarization for resolution of chronic inflammation via exosome-shuttled let-7b. , 13 , pp. 0642-6 doi:10.1186/s12967-015-0642-6 Tier 1
  10. Cosenza, S., Ruiz, M., Toupet, K., Jorgensen, C. and Noël, D. (2017). Mesenchymal stem cells derived exosomes and microparticles protect cartilage and bone from degradation in osteoarthritis. , 7 , pp. 15376-8 doi:10.1038/s41598-017-15376-8 Tier 1
  11. Qin, Y., Wang, L., Gao, Z., Chen, G. and Zhang, C. (2016). Bone marrow stromal/stem cell-derived extracellular vesicles regulate osteoblast activity and differentiation in vitro and promote bone regeneration in vivo. , 6 , pp. 21961 doi:10.1038/srep21961 Tier 1
  12. Shi, Z., Wang, Q. and Jiang, D. (2019). Extracellular vesicles from bone marrow-derived multipotent mesenchymal stromal cells regulate inflammation and enhance tendon healing. , 17 doi:10.1186/s12967-019-1960-x Tier 1
  13. Zhang, B., Wang, M., Gong, A., Zhang, X., Wu, X., Zhu, Y., Shi, H., Wu, L., Zhu, W., Qian, H. and Xu, W. (2015). HucMSC-exosome mediated-Wnt4 signaling is required for cutaneous wound healing. , 33 , pp. 2158–2168 doi:10.1002/stem.1771 Tier 1
  14. Xin, H., Li, Y., Cui, Y., Yang, J.J., Zhang, Z.G. and Chopp, M. (2013). Systemic administration of exosomes released from mesenchymal stromal cells promote functional recovery and neurovascular plasticity after stroke in rats. , 33 , pp. 1711–1715 doi:10.1038/jcbfm.2013.152 Tier 1
  15. Arslan, F., Lai, R.C., Smeets, M.B., Akber, L., Choo, A., Knol, E.N., Timmers, L., Lee, C.N., El Oakley, R.M., Pasterkamp, G., de Kleijn, D.P. and Lim, S.K. (2013). Mesenchymal stem cell-derived exosomes increase ATP levels, decrease oxidative stress and activate PI3K/Akt pathway to enhance myocardial viability and prevent adverse remodeling after myocardial ischemia/reperfusion injury. , 10 , pp. 301–312 doi:10.1016/j.scr.2013.01.002 Tier 1
  16. Tompkins, B.A., DiFede, D.L., Khan, A., Landin, A.M., Schulman, I.H., Pujol, M.V., Heldman, A.W., Miki, R., Goldschmidt-Clermont, P.J., Goldstein, B.J., Mushtaq, M., Levis-Dusseau, S., Byrnes, J.J., Lowery, M., Natsumeda, M., Delber, C., Balber, R., Oliva, A.A. and Hare, J.M. (2017). Allogeneic mesenchymal stem cells ameliorate aging frailty: A phase II randomized, double-blind, placebo-controlled clinical trial. , 72 , pp. 1513–1522 doi:10.1093/gerona/glx137 Tier 1
  17. Witwer, K.W., Van Balkom, B.W.M., Bruno, S., Choo, A., Dominici, M., Gimona, M., Hill, A.F., De Kleijn, D., Koh, M., Lai, R.C., Mitsialis, S.A., Ortiz, L.A., Rohde, E., Asada, T., Toh, W.S., Weiss, D.J., Zheng, L., Giebel, B. and Lim, S.K. (2019). Defining mesenchymal stromal cell (MSC)-derived small extracellular vesicles for therapeutic applications. , 8 doi:10.1080/20013078.2019.1609206 Tier 1
  18. Lötvall, J., Hill, A.F., Hochberg, F., Buzás, E.I., Di Vizio, D., Gardiner, C., Gho, Y.S., Kurochkin, I.V., Mathivanan, S., Quesenberry, P., Sahoo, S., Tahara, H., Wauben, M.H., Witwer, K.W. and Théry, C. (2014). Minimal experimental requirements for definition of extracellular vesicles and their functions: A position statement from the International Society for Extracellular Vesicles. , 3 doi:10.3402/jev.v3.26913 Tier 1
  19. Mendt, M., Rezvani, K. and Shpall, E. (2019). Mesenchymal stem cell-derived exosomes for clinical use. , pp. 789–792 doi:10.1038/s41409-019-0616-z Tier 1
  20. Zhu, Y., Huang, C., Zheng, L., Li, Q., Ge, J., Geng, S., Zhai, M., Chen, X., Yuan, H., Li, Y., Jia, W., Sun, K., Li, Y., Ye, T., Zhao, Z., Liu, H., Liu, Z. and Jiang, H. (2024). Safety and efficacy of umbilical cord tissue-derived mesenchymal stem cells in the treatment of patients with aging frailty: A phase I/II randomized, double-blind, placebo-controlled study. , 15 , pp. 03707-2 doi:10.1186/s13287-024-03707-2 Tier 1

Ready to Learn More?

Discover if regenerative medicine is right for you.

Take Free Assessment